SAVAYSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7365205 | DAIICHI SANKYO INC | Diamine derivatives |
Apr, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9149532 | DAIICHI SANKYO INC | Pharmaceutical composition |
Mar, 2028
(3 years from now) | |
Savaysa is owned by Daiichi Sankyo Inc.
Savaysa contains Edoxaban Tosylate.
Savaysa has a total of 2 drug patents out of which 0 drug patents have expired.
Savaysa was authorised for market use on 08 January, 2015.
Savaysa is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Savaysa from 08 January, 2019.
The generics of Savaysa are possible to be released after 28 March, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-14) | Oct 18, 2026 |
| M(M-243) | Aug 09, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2020 |
Drugs and Companies using EDOXABAN TOSYLATE ingredient
NCE-1 date: 08 January, 2019
Market Authorisation Date: 08 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of SAVAYSA before it's drug patent expiration?
More Information on Dosage
SAVAYSA family patents
